Preclinical analysis of novel prognostic transcription factors and immune‑related gene signatures for bladder cancer via TCGA‑based bioinformatic analysis

Deng,Yuyou; Hong,Xin; Yu,Chengfan; Li,Hui; Wang,Qiang; Zhang,Yi; Wang,Tian; Wang,Xiaofeng

doi:10.3892/ol.2021.12605

Preclinical analysis of novel prognostic transcription factors and immune‑related gene signatures for bladder cancer via TCGA‑based bioinformatic analysis

Authors:
- Yuyou Deng
- Xin Hong
- Chengfan Yu
- Hui Li
- Qiang Wang
- Yi Zhang
- Tian Wang
- Xiaofeng Wang
View Affiliations

Affiliations: Department of Urology, Peking University International Hospital, Beijing 102206, P.R. China
Published online on: March 3, 2021 https://doi.org/10.3892/ol.2021.12605
Article Number: 344
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bladder cancer (BLCA) is a common malignancy of human urinary tract, whose prognosis is influenced by complex gene interactions. Immune response activity can act as a potential prognostic factor in BLCA. The present study established a prognostic model, based on the identification of tumor transcription factors (TFs) and immune‑related genes (IRGs), and further explored their therapeutic potential in BLCA. The enrichment scores of 29 IRG sets, identified in The Cancer Genome Atlas BLCA tumor samples, were quantified by single‑sample Gene Set Enrichment Analysis. The abundance of infiltrated immune cells in tumor tissues was determined using the Estimating Relative algorithm. Tumor‑related TFs and IRGs signatures were retrieved using Least Absolute Shrinkage and Selection Operator Cox regression analysis. A prognostic gene network was built using Pearson's correlation analysis as a means of predicting the regulatory relationship between prognostic TFs and IRGs. A nomogram was devised to also predict the overall survival (OS) rate of patients with BLCA. Based on the Genomics of Drug Sensitivity in Cancer data, potential therapeutic drugs were identified upon analyzing the relationship between the expression level of prognostic genes and respective IC₅₀ values. In vitro experiments were implemented for further validation. Respective TF binding profiles were acquired from the JASPAR 2020 database. The elevated infiltration of CD8⁺ T Cells was correlated with an improved OS of patients with BLCA. An innovative prognostic model for BLCA was then constructed that composed of nine putative gene markers: CXCL13, prepronociceptin, microtubule‑associated protein tau, major histocompatibility class I polypeptide‑related sequence B, prostaglandin E2 receptor EP3 subtype, IL20RA, proepiregulin, early growth response protein 1 and FOS‑related antigen 1 (FOSL1). Furthermore, a theoretical basis for the correlation between the prognostic TFs and IRGs was reported. For this, 10 potentially effective drugs targeting the TFs in the present model for patients with BLCA were identified. It was then verified that downregulation of FOSL1 can lead to an enhanced sensitivity of the TW37 in T24 bladder cancer cells. Overall, the present prognostic model demonstrated a robust capability of predicting OS of patients with BLCA. Hence, the gene markers identified could be applied for targeted therapies against BLCA.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
2	Babjuk M: Trends in bladder cancer incidence and mortality: Success or disappointment? Eur Urol. 71:109–110. 2017. View Article : Google Scholar : PubMed/NCBI
3	Knowles MA and Hurst CD: Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar : PubMed/NCBI
4	Nadal R and Bellmunt J: Management of metastatic bladder cancer. Cancer Treat Rev. 76:10–21. 2019. View Article : Google Scholar : PubMed/NCBI
5	Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol. 10:1066–1073. 1992. View Article : Google Scholar : PubMed/NCBI
6	Zou W, Wolchok JD and Chen L: PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 8:328rv3242016. View Article : Google Scholar
7	Aggen DH and Drake CG: Biomarkers for immunotherapy in bladder cancer: A moving target. J Immunother Cancer. 5:942017. View Article : Google Scholar : PubMed/NCBI
8	Carosella ED, Ploussard G, LeMaoult J and Desgrandchamps F: A systematic review of immunotherapy in urologic cancer: Evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 68:267–279. 2015. View Article : Google Scholar : PubMed/NCBI
9	Xue Y, Tong L, Liu F, Liu A, Liu A, Zeng S, Xiong Q, Yang Z, He X, Sun Y and Xu C: Tumor infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer. Oncol Rep. 42:581–594. 2019.PubMed/NCBI
10	Miyake M, Tatsumi Y, Gotoh D, Ohnishi S, Owari T, Iida K, Ohnishi K, Hori S, Morizawa Y, Itami Y, et al: Regulatory T Cells and tumor-associated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical bacille calmette-guerin: A long-term follow-up study of a Japanese cohort. Int J Mol Sci. 18:2017. View Article : Google Scholar : PubMed/NCBI
11	Jiang W, Zhu D, Wang C and Zhu Y: An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC). Cancer Med. 9:2774–2790. 2020. View Article : Google Scholar : PubMed/NCBI
12	Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 4:26122013. View Article : Google Scholar : PubMed/NCBI
13	Hanzelmann S, Castelo R and Guinney J: GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
14	Witten DM and Tibshirani R: A framework for feature selection in clustering. J Am Stat Assoc. 105:713–726. 2010. View Article : Google Scholar : PubMed/NCBI
15	Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
16	da Silveira WA, Hazard ES, Chung D and Hardiman G: Molecular profiling of RNA tumors using high-throughput RNA sequencing: From raw data to systems level analyses. Methods Mol Biol. 1908:185–204. 2019. View Article : Google Scholar : PubMed/NCBI
17	Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e472015. View Article : Google Scholar : PubMed/NCBI
18	Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J, Berger P, Desborough V, Smith T, Campbell J, et al: ImmPort: Disseminating data to the public for the future of immunology. Immunol Res. 58:234–239. 2014. View Article : Google Scholar : PubMed/NCBI
19	Wan B, Liu B, Huang Y, Yu G and Lv C: Prognostic value of immune-related genes in clear cell renal cell carcinoma. Aging (Albany NY). 11:11474–11489. 2019. View Article : Google Scholar : PubMed/NCBI
20	Yu G, Wang LG, Han Y and He QY: ClusterProfiler: An R package for comparing biological themes among gene clusters. Omics. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
21	Heagerty PJ and Zheng Y: Survival model predictive accuracy and ROC curves. Biometrics. 61:92–105. 2005. View Article : Google Scholar : PubMed/NCBI
22	Fornes O, Castro-Mondragon JA, Khan A, Khan A, Lee RVD, Zhang X, Richmond PA, Modi BP, Correard S, Gheorghe M, et al: JASPAR 2020: Update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 48:D87–d92. 2020.PubMed/NCBI
23	Song J, Deng Z, Su J, Yuan D, Liu J and Zhu J: Patterns of immune infiltration in hnc and their clinical implications: A gene expression-based study. Front Oncol. 9:12852019. View Article : Google Scholar : PubMed/NCBI
24	Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
25	Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, et al: EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol. 71:447–461. 2017. View Article : Google Scholar : PubMed/NCBI
26	Felsenstein KM and Theodorescu D: Precision medicine for urothelial bladder cancer: Update on tumour genomics and immunotherapy. Nat Rev Urol. 15:92–111. 2018. View Article : Google Scholar : PubMed/NCBI
27	Shu B, Zhang J, Sethuraman V, Cui G, Yi X and Zhong G: Transcriptome analysis of Spodoptera frugiperda Sf9 cells reveals putative apoptosis-related genes and a preliminary apoptosis mechanism induced by azadirachtin. Sci Rep. 7:132312017. View Article : Google Scholar : PubMed/NCBI
28	Rui X, Shao S, Wang L and Leng J: Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram. BMC Cancer. 19:11792019. View Article : Google Scholar : PubMed/NCBI
29	Zhang S, Zhang E, Long J, Hu Z, Peng J, Liu L, Tang F, Li L, Ouyang Y and Zeng Z: Immune infiltration in renal cell carcinoma. Cancer Sci. 110:1564–1572. 2019. View Article : Google Scholar : PubMed/NCBI
30	Rosenberg J and Huang J: CD8(+) T Cells and NK cells: Parallel and complementary soldiers of immunotherapy. Curr Opin Chem Eng. 19:9–20. 2018. View Article : Google Scholar : PubMed/NCBI
31	He QF, Xu Y, Li J, Huang ZM, Li XH and Wang X: CD8⁺ T-cell exhaustion in cancer: Mechanisms and new area for cancer immunotherapy. Brief Funct Genomics. 18:99–106. 2019. View Article : Google Scholar : PubMed/NCBI
32	Mitchell S, Vargas J and Hoffmann A: Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med. 8:227–241. 2016. View Article : Google Scholar : PubMed/NCBI
33	Imanishi T and Saito T: T Cell co-stimulation and functional modulation by innate signals. Trends Immunol. 41:200–212. 2020. View Article : Google Scholar : PubMed/NCBI
34	Asprodites N, Zheng L, Geng D, Velasco-Gonzalez C, Sanchez-Perez L and Davila E: Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. Faseb J. 22:3628–3637. 2008. View Article : Google Scholar : PubMed/NCBI
35	Chi D, Xu W, Tao X, Zhang T and Cui Y: PD-L1 expression in colorectal cancer and its relationship with TLR-4 expression. J Buon. 25:1423–1429. 2020.PubMed/NCBI
36	Dan L, Liu L, Sun Y, Song J, Yin Q, Zhang G, Qi F, Hu Z, Yang Z, Zhou Z, et al: The phosphatase PAC1 acts as a T cell suppressor and attenuates host antitumor immunity. Nat Immunol. 21:287–297. 2020. View Article : Google Scholar : PubMed/NCBI
37	Elangovan IM, Vaz M, Tamatam CR, Potteti HR, Reddy NM and Reddy SP: FOSL1 promotes kras-induced lung cancer through amphiregulin and cell survival gene regulation. Am J Respir Cell Mol Biol. 58:625–635. 2018. View Article : Google Scholar : PubMed/NCBI
38	Luo YZ, He P and Qiu MX: FOSL1 enhances growth and metastasis of human prostate cancer cells through epithelial mesenchymal transition pathway. Eur Rev Med Pharmacol Sci. 22:8609–8615. 2018.PubMed/NCBI
39	Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala L, Jiang D, Nagaraja A, Ozpolat B, et al: PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine. 40:290–304. 2019. View Article : Google Scholar : PubMed/NCBI
40	Coupland KG, Kim WS, Halliday GM, Hallupp M, Dobson-Stone C and Kwok JB: Role of the long non-coding RNA MAPT-AS1 in regulation of microtubule associated protein tau (MAPT) expression in parkinson's disease. PLoS One. 11:e01579242016. View Article : Google Scholar : PubMed/NCBI
41	Wosnitzer MS, Domingo-Domenech J, Castillo-Martin M, Ritch C, Mansukhani M, Petrylack DP, Benson MC, McKiernan JM and Cordon-Cardo C: Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. J Urol. 186:2094–2100. 2011. View Article : Google Scholar : PubMed/NCBI
42	Riese DJ 2nd and Cullum RL: Epiregulin: roles in normal physiology and cancer. Semin Cell Dev Biol. 28:49–56. 2014. View Article : Google Scholar : PubMed/NCBI
43	Cao R, Yuan L, Ma B, Wang G, Qiu W and Tian Y: An EMT-related gene signature for the prognosis of human bladder cancer. J Cell Mol Med. 24:605–617. 2020. View Article : Google Scholar : PubMed/NCBI
44	Chen Z, Liu G, Hossain A, Danilova IG, Bolkov MA, Liu G, Tuzankina IA and Tan W: A co-expression network for differentially expressed genes in bladder cancer and a risk score model for predicting survival. Hereditas. 156:242019. View Article : Google Scholar : PubMed/NCBI
45	Liu S, Suo J, Wang C, Sun X, Wang D, He L, Zhang Y and Li W: Prognostic significance of low miR-144 expression in gastric cancer. Cancer Biomark. 20:547–552. 2017. View Article : Google Scholar : PubMed/NCBI